CHICAGO, IL / ACCESSWIRE / December 2, 2022 / Cosmos Holdings d/b/a Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, provided a summary regarding recent share activity, including the participation of CEO, Greg Siokas on all capital raises. Management reiterates its belief in the financial strength of Cosmos Health, and its commitment to the growth and profitability of the Company.

In February and October of 2022 Cosmos successfully conducted two separate rounds of financings, with the combined proceeds of $13.5M. Furthermore, the Company has noted significant exercises of warrants in the month of November. As such, management now expects that by the end of Year End 2022, debt should decline by roughly 50% versus prior year levels.

Mr. Siokas has not sold any shares and has no plans to sell any of his shares.

Greg Siokas, Chief Executive Officer of Cosmos Health stated, "I am excited to see Cosmos emerge in to in a stronger financial position. We have had two successful capital raises in 2022, both of which I happily participated in for a combined amount of $3M. Since 2019, I have invested over $10.6M at an average price of $5.25 of my personal assets in Cosmos, as I have always believed in its growth and profitability prospects. My interests have always been and will continue to be aligned with those of shareholders, and I am constantly working to make sure shareholder value is realized. Given our new financial stability, I am hopeful about the future of Cosmos and our ability to rapidly grow as an international health and wellness company with multiple strong brands. I want to thank our shareholders and our team members who have helped us through this journey."

About Cosmos Health, Inc

Cosmos Health Inc. (Nasdaq:COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation." Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at and .

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Lytham Partners, LLC
Ben Shamsian
E: shamsian@lythampartners.com
P: 646-829-9701

SOURCE: Cosmos Holdings, Inc.